GSB-106

What is GSB-106?

GSB-106 is a synthetic dimeric dipeptide designed to reproduce the bioactive conformation of the fourth beta-turn loop of brain-derived neurotrophic factor (BDNF) — the region of the full-length neurotrophin thought to drive binding to the TrkB receptor. It was developed at the V.V. Zakusov Research Institute of Pharmacology (part of the Russian Academy of Medical Sciences) in Moscow by the T.A. Gudasheva and S.B. Seredenin group, as the BDNF-mimetic counterpart to their NGF-mimetic GK-2. The stated design goal was a low-molecular-weight, metabolically stable molecule that could reproduce TrkB-mediated neurotrophic signaling in a form small enough to be orally active — something full-length BDNF, a 27 kDa protein, cannot be. GSB-106 has been reported in Russian peer-reviewed literature to produce antidepressant-like, analgesic and neuroprotective effects in standard rodent models. It has not, to our knowledge, been tested in a published human clinical trial.

What GSB-106 Is Investigated For

GSB-106 is a mechanistically interesting molecule: a dimeric dipeptide designed to mimic the TrkB-binding loop of BDNF and to reproduce neurotrophin signaling in a drug-like, orally bioavailable format. The strongest support comes from preclinical rodent studies out of the Gudasheva and Seredenin group at the Zakusov Institute, which report antidepressant-like activity in the forced-swim and tail-suspension tests, restored exploratory and avoidance behavior in a foot-shock depression model, analgesia in hot-plate and tail-flick tests, and neuroprotection in a rat middle-cerebral-artery-occlusion stroke model. Claims that GSB-106 itself has been tested in beta-amyloid Alzheimer's models or MPTP parkinsonian rodents do not survive checking — that work belongs to the sibling loop-1 mimetic GSB-214. The honest caveats are substantial and should be stated directly: almost all of the published efficacy data comes from a single research program, the one independent attempt to confirm the core mechanism — direct TrkB activation — came back negative, and — most importantly — no completed human randomized controlled trial of GSB-106 for depression, anxiety, stroke, or any other indication appears in the indexed clinical trial literature. Rodent behavioral despair assays are known to translate imperfectly to human depression. GSB-106 should be understood as a preclinical BDNF-mimetic drug candidate with a coherent rationale, not as a validated human therapy. It is also not the same thing as BDNF itself, and it is not interchangeable with BDNF-upregulating interventions like exercise, SSRIs, or ketamine, each of which works through different mechanisms with a different evidence base in humans.

History & Discovery

GSB-106 comes out of a long-running Russian medicinal-chemistry program at the V.V. Zakusov Research Institute of Pharmacology in Moscow, part of the Russian Academy of Medical Sciences. The program was led by Tatiana A. Gudasheva, with Sergey B. Seredenin as institute director and co-investigator, and it began from a deliberate design question: the neurotrophins — NGF, BDNF, NT-3, NT-4 — are among the most biologically interesting molecules in neuroscience, but they are large, unstable proteins that do not cross the blood-brain barrier after peripheral administration and are impractical as systemic drugs. Could the bioactive core of a neurotrophin be reproduced in a small molecule that kept the receptor-activating pharmacology but discarded the pharmaceutically inconvenient bulk? The group's approach was to focus on the individual beta-turn loops of each neurotrophin — the loops that published crystallographic and mutagenesis work had implicated in receptor binding — and to build small, symmetric dimeric dipeptides shaped to reproduce those loops in isolation. Dimerization was deliberate: the native neurotrophins are homodimers that engage their Trk receptors as dimers, and the Gudasheva design attempts to recapitulate that geometry at a much smaller scale. GK-2 was the first widely discussed compound from the program — a dimeric dipeptide mimetic of loop 4 of NGF, targeting TrkA, with reported neuroprotective activity in preclinical stroke and neurodegeneration models. GSB-106 is the BDNF counterpart: the loop 4 mimetic of BDNF, targeting TrkB. Its chemical structure — a bis-(N-monosuccinyl-L-seryl-L-lysine) hexamethylenediamide — reflects the same design grammar as GK-2 (bis-(N-monosuccinyl-L-glutamyl-L-lysine) hexamethylenediamide). It is easily confused with GSB-214, the group's BDNF loop-1 mimetic, which is the methionine-containing bis-(N-monosuccinyl-L-methionyl-L-serine) heptamethylenediamide — much of the Alzheimer's and Parkinson's literature circulating under the GSB-106 name actually belongs to GSB-214 with a different amino-acid pair and a BDNF-derived receptor target. Published preclinical work on GSB-106 spans antidepressant-like activity in forced-swim and tail-suspension tests, analgesia in hot-plate and tail-flick tests, suppression of morphine-withdrawal signs, and neuroprotection in focal cerebral ischemia. The program has also reported mechanistic data showing TrkB activation and downstream Erk and Akt phosphorylation in cultured neurons. Most of this work has been published in Russian pharmacology and neuroscience journals, often in English-language translations indexed on PubMed, but the bulk of the efficacy record comes from the Gudasheva and Seredenin group rather than from independent Western laboratories. Public information about advancement into formal human clinical trials is limited; as of this writing, no completed randomized controlled trial of GSB-106 for any indication has been indexed in the major clinical trial registries we can verify.

How It Works

GSB-106 is a tiny synthetic molecule shaped to copy the part of BDNF — a natural brain growth factor — that latches onto the TrkB receptor on neurons. By engaging TrkB, it is designed to switch on some of the same growth and survival signals that BDNF normally turns on, without requiring the full-size BDNF protein.

GSB-106 is a bis-(N-monosuccinyl-L-seryl-L-lysine) hexamethylenediamide — a symmetric dimeric dipeptide built by linking two Ser-Lys units through a hexamethylenediamine spacer attached via succinyl groups. The design is based on the reported bioactive conformation of the fourth beta-turn loop of BDNF, which contacts the TrkB receptor in the native neurotrophin. In preclinical studies from the Gudasheva and Seredenin group, GSB-106 is reported to activate TrkB and its canonical downstream signaling cascades — PI3K/Akt (survival), MAPK/ERK (plasticity and growth), and PLC-gamma — at sub-micromolar concentrations in cultured neurons — though at its optimal 100 nM concentration it reproduces only about 37 percent of the maximal neurotrophic effect of BDNF itself, while producing antidepressant-like behavioral effects in rodents after oral dosing. Reported effects include restoration of hippocampal BDNF-related signaling after stress, neuroprotection against glutamate excitotoxicity in vitro, protection of cultured HT-22 neurons against hydrogen peroxide and glutamate, and a 24 percent reduction in brain damage volume with restored hippocampal and striatal neurogenesis when dosing began 24 hours after middle cerebral artery occlusion in rats. Whether the downstream signaling reproduces the full repertoire of native BDNF-TrkB signaling — including the specific receptor trafficking and sustained signaling patterns that distinguish endogenous neurotrophin responses from synthetic ligand engagement — is not fully established. A harder problem sits upstream. The only published attempt by an outside laboratory to detect direct TrkB engagement failed: a Celon Pharma group that re-synthesised GSB-106 found no measurable binding to the TrkB extracellular domain, no receptor phosphorylation, no positive allosteric modulation of BDNF and no TrkB dimerisation, while BDNF itself registered a dissociation constant of 0.093 micromolar in the same assays. That group also reported GSB-106 was unstable in their metabolic-stability system, which is a real caveat on how much weight the negative result can carry.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about GSB-106:

• 01Direct target engagement — the originating group has never published a binding constant for GSB-106 at TrkB, and the one outside laboratory that looked found no detectable binding to the TrkB extracellular domain, no receptor phosphorylation and no receptor dimerisation (while also noting the compound was unstable in their assay system). Until an independent group reproduces direct TrkB engagement, the BDNF-mimetic mechanism should be treated as proposed rather than demonstrated.
• 02Any completed human randomized controlled trial — no published Phase II or III study has tested GSB-106 in humans with depression, anxiety, stroke, Alzheimer's, or any other indication, and human efficacy therefore remains unproven.
• 03Human pharmacokinetics — oral bioavailability, plasma and CNS exposure, half-life, and metabolism in humans have not been characterized in any peer-reviewed publication we can verify.
• 04Independent preclinical replication — the efficacy record for GSB-106 comes largely from the Gudasheva and Seredenin group at the Zakusov Institute; independent reproduction by unaffiliated laboratories is limited, and the one outside group that tested direct TrkB engagement found none.
• 05Chronic TrkB-mimetic safety — sustained TrkB activation has theoretical implications for cell proliferation and for neurotrophin receptor desensitization that have not been studied in long-duration animal studies at doses relevant to proposed human exposure.
• 06Comparative efficacy vs. established antidepressants and vs. other BDNF-upregulating interventions — GSB-106 has not been compared head-to-head with SSRIs, ketamine, exercise, or other BDNF-modulating approaches in humans, so relative efficacy and relative safety are unknown.
• 07Signaling fidelity vs. native BDNF — whether a small-molecule loop mimetic reproduces the full temporal and spatial pattern of native BDNF-TrkB signaling in vivo, or only a subset, has not been resolved and has implications for which BDNF-mediated effects should and should not be expected.
• 08Real-world product quality — research-chemical-channel GSB-106 lacks the identity, purity, and chain-of-custody verification that would let even informed users know what they are taking.

Forms & Administration

GSB-106 is reported in the preclinical literature to be active after oral administration in rodents at low-milligram-per-kilogram doses, which is unusual for a peptide and is a core design feature emphasized by the Gudasheva group. A tablet dosage form has been formulated and tested preclinically — its relative bioavailability in rabbits was about 161 percent of the loose substance, and in rats the tablet was antidepressant-effective from 0.01 mg/kg, roughly fifty-fold below the loose substance — but there is still no approved human dosage form and no pharmaceutical-grade product. Any research-chemical-channel GSB-106 should be treated as a research compound of unverified identity and purity.

Common Questions

Who GSB-106 Is NOT For

Drug & Supplement Interactions

No formal drug-interaction studies for GSB-106 exist in the indexed clinical literature. Theoretical considerations follow from the proposed TrkB-biased signaling mechanism and the pharmacology of overlapping CNS-active medications. Concurrent use with SSRIs, SNRIs, tricyclic antidepressants, ketamine, esketamine, or psychedelic compounds could theoretically interact at the level of overlapping BDNF/TrkB downstream signaling (PI3K/Akt, MAPK/ERK) — all of these drug classes have been linked to BDNF upregulation by indirect mechanisms — but no clinical data on additive or synergistic effects exist. Concurrent treatment with NTRK-targeted kinase inhibitors used for fusion-positive cancers (entrectinib, larotrectinib, repotrectinib) is pharmacologically antagonistic and should be avoided. Concurrent administration with the sibling NGF-mimetic GK-2 from the same originating program is common in preclinical research but has not been studied for safety or for additive vs antagonistic effects in any controlled setting. Patients on any chronic CNS-active medication should disclose all concurrent agents to a research-protocol investigator before any GSB-106 use is considered.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions